
Matteo Tebaldi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3738981/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Circulation, 2012, 125, 2015-2026.	1.6	640
2	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet, The, 2012, 380, 1482-1490.	6.3	412
3	Diagnostic Accuracy of Fast Computational Approaches to DeriveÂFractional Flow Reserve FromÂDiagnostic Coronary Angiography. JACC: Cardiovascular Interventions, 2016, 9, 2024-2035.	1.1	394
4	Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 57, 2474-2483.	1.2	315
5	Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. Journal of the American College of Cardiology, 2015, 65, 805-815.	1.2	248
6	Diagnostic Performance of Inâ€Procedure Angiographyâ€Derived Quantitative Flow Reserve Compared to Pressureâ€Derived Fractional Flow Reserve: The FAVOR II Europeâ€Japan Study. Journal of the American Heart Association, 2018, 7, .	1.6	240
7	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	6.3	215
8	Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting. JACC: Cardiovascular Interventions, 2012, 5, 268-277.	1.1	162
9	ls Bare-Metal Stent Implantation StillÂJustifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	1.1	135
10	Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 20-28.	1.1	124
11	Transradial Coronary Catheterization and Intervention Across the Whole Spectrum of Allen Test Results. Journal of the American College of Cardiology, 2014, 63, 1833-1841.	1.2	123
12	Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). European Heart Journal, 2013, 34, 909-919.	1.0	108
13	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. European Heart Journal, 2010, 31, 35-49.	1.0	103
14	Prognostic Value of QFR Measured Immediately After Successful Stent Implantation. JACC: Cardiovascular Interventions, 2019, 12, 2079-2088.	1.1	103
15	Evolving Routine Standards in InvasiveÂHemodynamic Assessment of Coronary Stenosis. JACC: Cardiovascular Interventions, 2018, 11, 1482-1491.	1.1	85
16	Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?. Journal of the American College of Cardiology, 2007, 50, 1132-1137.	1.2	82
17	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment–Elevation Myocardial Infarction and Multivessel Disease. Circulation: Cardiovascular Interventions, 2018, 11, e006023.	1.4	80
18	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation, 2020, 142, 441-454.	1.6	67

#	Article	IF	CITATIONS
19	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention. American Heart Journal, 2010, 160, 804-811.	1.2	66
20	Radiation Exposure and Vascular AccessÂinÂAcute Coronary Syndromes. Journal of the American College of Cardiology, 2017, 69, 2530-2537.	1.2	61
21	Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2020, 41, 4103-4110.	1.0	59
22	Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis. Journal of the American College of Cardiology, 2014, 63, 506-512.	1.2	58
23	Poor response to clopidogrel: current and future options for its management. Journal of Thrombosis and Thrombolysis, 2010, 30, 319-331.	1.0	53
24	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. European Heart Journal, 2014, 35, 2524-2529.	1.0	49
25	The Assessment of Scales of Frailty and Physical Performance Improves Prediction of Major Adverse Cardiac Events in Older Adults with Acute Coronary Syndrome. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1113-1119.	1.7	49
26	Genetic determinants of on-clopidogrel high platelet reactivity. Platelets, 2011, 22, 399-407.	1.1	48
27	Novel Indices of Coronary Physiology. Circulation: Cardiovascular Interventions, 2020, 13, e008487.	1.4	44
28	Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter <scp>I</scp> talian Registry (the <scp>FREAK</scp> Study). Catheterization and Cardiovascular Interventions, 2016, 88, 555-562.	0.7	40
29	The 5-Year Clinical Outcomes After a Randomized Comparison of Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2009, 54, 1900-1901.	1.2	38
30	Angio-Based Index of Microcirculatory Resistance for the Assessment of the Coronary Resistance: A Proof of Concept Study. Journal of Interventional Cardiology, 2020, 2020, 1-4.	0.5	36
31	Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. Platelets, 2016, 27, 484-487.	1.1	32
32	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2021, 77, 1165-1178.	1.2	32
33	Incidence, prognostic impact, and optimal definition of contrastâ€induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the allâ€comer <scp>PRODICY</scp> trial. Catheterization and Cardiovascular Interventions. 2015. 86. E19-27.	0.7	30
34	Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascoside treatment. A randomized study. Pharmacological Research, 2015, 97, 1-6.	3.1	30
35	A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). EuroIntervention, 2016, 12, 1223-1230.	1.4	29
36	On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention: TableÂ1. Thorax, 2014, 69, 80-81.	2.7	28

#	Article	IF	CITATIONS
37	Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial. American Heart Journal, 2020, 229, 100-109.	1.2	24
38	Coronary Microvascular Dysfunction: PET, CMR and CT Assessment. Journal of Clinical Medicine, 2021, 10, 1848.	1.0	24
39	Thrombin generation assay. Blood Coagulation and Fibrinolysis, 2012, 23, 680-687.	0.5	22
40	Coagulation Factors and Recurrence of Ischemic and Bleeding Adverse Events in Patients with Acute Coronary Syndromes. Thrombosis Research, 2013, 132, 151-157.	0.8	22
41	Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. EuroIntervention, 2017, 13, 78-86.	1.4	21
42	Effects of preâ€hospital clopidogrel administration on early and late residual platelet reactivity in STâ€segment elevation myocardial infarction patients undergoing primary intervention. Journal of Thrombosis and Haemostasis, 2013, 11, 192-194.	1.9	19
43	Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study. American Heart Journal. 2013. 166. 831-838.	1.2	18
44	Safety and Feasibility of Transradial Mini-Invasive Balloon Aortic Valvuloplasty. JACC: Cardiovascular Interventions, 2017, 10, 1375-1377.	1.1	18
45	Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX – RAdiation Dose study (RAD-MATRIX). Cardiovascular Revascularization Medicine. 2014. 15. 209-213.	0.3	17
46	Comparison of quantitative flow ratio, Pd/Pa and diastolic <scp>hyperemiaâ€free</scp> ratio versus fractional flow reserve in <scp>nonâ€culprit</scp> lesion of patients with non <scp>ST</scp> â€segment elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2021, 98, 1057-1065.	0.7	17
47	Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. Journal of Thrombosis and Haemostasis, 2008, 6, 1824-1826.	1.9	15
48	Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison. International Journal of Cardiovascular Imaging, 2016, 32, 211-223.	0.7	15
49	Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 32-40.	1.8	15
50	Usefulness of Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina Pectoris. American Journal of Cardiology, 2021, 139, 22-27.	0.7	15
51	Randomized, doubleâ€blind comparison of effects of abiciximab bolus only vs. onâ€label regimen on exÂvivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. Journal of Thrombosis and Haemostasis, 2010, 8, 1903-1911.	1.9	14
52	Seven french radial artery access for PCI: A prospective single-center experience. International Journal of Cardiology, 2014, 176, 1074-1075.	0.8	14
53	Fractional flow reserve implementation in daily clinical practice: A European survey. International Journal of Cardiology, 2016, 207, 206-207.	0.8	14
54	Safety, efficacy and impact on frailty of mini-invasive radial balloon aortic valvuloplasty. Heart, 2021, 107, 874-880.	1.2	13

#	Article	IF	CITATIONS
55	Enhanced stent visualization systems during PCI: A case series and review of literature. Journal of Cardiology Cases, 2015, 12, 1-5.	0.2	12
56	Safety and efficacy of coronary sinus narrowing in chronic refractory angina: Insights from the RESOURCE study. International Journal of Cardiology, 2021, 337, 29-37.	0.8	12
57	A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS ONE, 2017, 12, e0182124.	1.1	12
58	Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study. Cardiovascular Drugs and Therapy, 2019, 33, 523-532.	1.3	11
59	Angiographyâ€derived versus invasivelyâ€determined index of microcirculatory resistance in the assessment of coronary microcirculation: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2022, 99, 2018-2025.	0.7	11
60	Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. International Journal of Cardiology, 2013, 167, 296-297.	0.8	10
61	Abciximab: a reappraisal of its use in coronary care. Biologics: Targets and Therapy, 2008, 2, 29.	3.0	8
62	Contrast Associated Acute Kidney Injury and Mortality in Older Adults with Acute Coronary Syndrome: A Pooled Analysis of the FRASER and HULK Studies. Journal of Clinical Medicine, 2021, 10, 2151.	1.0	8
63	Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study. American Heart Journal, 2018, 196, 113-118.	1.2	7
64	Adenosine-Free Indexes vs. Fractional Flow Reserve for Functional Assessment of Coronary Stenoses: Systematic Review and Meta-Analysis. International Journal of Cardiology, 2020, 299, 93-99.	0.8	7
65	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale. Journal of Cardiovascular Translational Research, 2021, 14, 110-119.	1.1	7
66	Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention. Circulation Journal, 2017, 81, 82-89.	0.7	7
67	Safety evaluation of tirofiban. Expert Opinion on Drug Safety, 2010, 9, 801-819.	1.0	6
68	Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study. Cardiology, 2018, 140, 74-82.	0.6	6
69	Fractional flow reserve: Current applications and overview of the available data. World Journal of Clinical Cases, 2015, 3, 678.	0.3	6
70	Acetylcholine Use in Modern Cardiac Catheterization Laboratories: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 1129.	1.0	6
71	Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 2012, 10, 153-156.	1.9	5
72	Quantitative flow ratio as a new tool for angiography-based physiological evaluation of coronary artery disease: a review. Future Cardiology, 2021, 17, 1435-1452.	0.5	4

#	Article	IF	CITATIONS
73	Complete versus culpritâ€only strategy in older MI patients with multivessel disease. Catheterization and Cardiovascular Interventions, 2022, 99, 970-978.	0.7	4
74	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. International Journal of Cardiology, 2019, 277, 60-65.	0.8	2
75	Index of microcirculatory resistance assessment in patients with new diagnosis of left ventricular dilatation without significant coronary artery lesions: IMPAIRED pilot trial. European Journal of Heart Failure, 2020, 22, 561-563.	2.9	2
76	One-Year Clinical Outcomes of Forty-Eight Millimeter Everolimus-Eluting Stent Implanted in Very Long Lesions: A Propensity-Matched Comparison (The FREIUS Study). Journal of Invasive Cardiology, 2018, 30, 133-137.	0.4	2
77	Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic Review. Cardiovascular Drugs and Therapy, 2024, 38, 151-161.	1.3	2
78	The impact of periprocedural myocardial infarction on mortality in older adults with non-ST-segment elevation acute coronary syndrome. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 546-552.	0.6	1
79	The unbearable lightness of the instantaneous wave-free ratio/fractional flow reserve discordance. Journal of Cardiovascular Medicine, 2022, 23, 116-118.	0.6	1
80	Low FFR equal to low ischemia: Really?. International Journal of Cardiology, 2018, 265, 81.	0.8	0
81	The management of patients with acute myocardial infarction: route to tailored therapy. International Journal of Cardiology, 2021, 343, 1-2.	0.8	0